Combined effects of cisplatin and photon or proton irradiation in cultured cells: radiosensitization, patterns of cell death and cell cycle distribution.


Journal

Journal of radiation research
ISSN: 1349-9157
Titre abrégé: J Radiat Res
Pays: England
ID NLM: 0376611

Informations de publication

Date de publication:
16 Nov 2020
Historique:
received: 10 04 2020
revised: 22 06 2020
accepted: 07 04 2020
pubmed: 4 9 2020
medline: 28 9 2021
entrez: 4 9 2020
Statut: ppublish

Résumé

The purpose of the current study was to investigate the biological effects of protons and photons in combination with cisplatin in cultured cells and elucidate the mechanisms responsible for their combined effects. To evaluate the sensitizing effects of cisplatin against X-rays and proton beams in HSG, EMT6 and V79 cells, the combination index, a simple measure for quantifying synergism, was estimated from cell survival curves using software capable of performing the Monte Carlo calculation. Cell death and apoptosis were assessed using live cell fluorescence imaging. HeLa and HSG cells expressing the fluorescent ubiquitination-based cell cycle indicator system (Fucci) were irradiated with X-rays and protons with cisplatin. Red and green fluorescence in the G1 and S/G2/M phases, respectively, were evaluated and changes in the cell cycle were assessed. The sensitizing effects of ≥1.5 μM cisplatin were observed for both X-ray and proton irradiation (P < 0.05). In the three cell lines, the average combination index was 0.82-1.00 for X-rays and 0.73-0.89 for protons, indicating stronger effects for protons. In time-lapse imaging, apoptosis markedly increased in the groups receiving ≥1.5 μM cisplatin + protons. The percentage of green S/G2/M phase cells at that time was higher when cisplatin was combined with proton beams than with X-rays (P < 0.05), suggesting more significant G2 arrest. Proton therapy plus ≥1.5 μM cisplatin is considered to be very effective. When combined with cisplatin, proton therapy appeared to induce greater apoptotic cell death and G2 arrest, which may partly account for the difference observed in the combined effects.

Identifiants

pubmed: 32880637
pii: 5897448
doi: 10.1093/jrr/rraa065
pmc: PMC7674701
doi:

Substances chimiques

Fluorescent Dyes 0
Ubiquitin 0
Cisplatin Q20Q21Q62J

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

832-841

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology.

Références

J Radiat Res. 2014 Jul;55(4):816-22
pubmed: 24824674
JAMA Oncol. 2017 Aug 10;3(8):e172032
pubmed: 28727865
Sci Rep. 2015 Sep 10;5:13961
pubmed: 26354413
Cell Biol Int. 2011 Apr;35(4):359-63
pubmed: 21231917
Oncogene. 2013 Aug 15;32(33):3789-97
pubmed: 23208502
Australas Phys Eng Sci Med. 2016 Sep;39(3):645-54
pubmed: 27271800
Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):175-81
pubmed: 24239385
Oncogene. 1999 Nov 11;18(47):6540-5
pubmed: 10597257
Cancer Cell Int. 2008 Mar 18;8:3
pubmed: 18348720
Int J Radiat Oncol Biol Phys. 1990 Nov;19(5):1183-9
pubmed: 2254110
Clin Transl Radiat Oncol. 2018 Feb 01;9:35-41
pubmed: 29594249
Int J Clin Oncol. 2018 Apr;23(2):353-360
pubmed: 29098520
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):95-102
pubmed: 27084632
J Radiat Res. 2019 Oct 23;60(5):612-621
pubmed: 31147697
Int J Radiat Oncol Biol Phys. 1979 Aug;5(8):1345-9
pubmed: 575118
Methods Mol Biol. 2015;1219:35-42
pubmed: 25308260
Cancer Res. 1999 Apr 1;59(7):1391-9
pubmed: 10197600
Int J Radiat Oncol Biol Phys. 1987 Mar;13(3):403-26
pubmed: 3549645
Adv Enzyme Regul. 1984;22:27-55
pubmed: 6382953
Histochem Cell Biol. 2018 Dec;150(6):649-659
pubmed: 30232589
Oncol Rep. 1999 Sep-Oct;6(5):949-57
pubmed: 10425285
Cell Cycle. 2017 Mar 19;16(6):565-573
pubmed: 28118061
Pharmacol Ther. 1984;25(3):297-326
pubmed: 6542679
Radiother Oncol. 2018 Jul;128(1):68-75
pubmed: 29910006
Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):776-784
pubmed: 29413288
Radiother Oncol. 2018 Jul;128(1):56-67
pubmed: 29861141
BMC Cell Biol. 2011 Jan 13;12:2
pubmed: 21226962
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Nucleic Acids Res. 2017 Apr 20;45(7):e55
pubmed: 28082389
Cancer Res. 1994 Dec 1;54(23):6201-9
pubmed: 7954467
F1000Res. 2016 May 23;5:962
pubmed: 27703665
Int J Radiat Oncol Biol Phys. 1981 Jul;7(7):929-33
pubmed: 7198110
Clin Cancer Res. 2005 May 1;11(9):3155-62
pubmed: 15867207
Phys Med. 2018 Jul;51:108-116
pubmed: 29908994
Strahlenther Onkol. 2018 Apr;194(4):343-351
pubmed: 29038831
Cancer Sci. 2016 Jul;107(7):1018-21
pubmed: 27110950
Med Phys. 2017 Nov;44(11):6061-6073
pubmed: 28880368

Auteurs

Hiromitsu Iwata (H)

Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City West Medical Center, 1-1-1 Hirate-cho, Kita-ku, Nagoya 462-8508, Japan.
Department of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.

Tsuyoshi Shuto (T)

Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto, 862-0973, Japan.

Shunsuke Kamei (S)

Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto, 862-0973, Japan.

Kohei Omachi (K)

Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto, 862-0973, Japan.

Masataka Moriuchi (M)

Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto, 862-0973, Japan.

Chihiro Omachi (C)

Department of Proton Therapy Physics, Nagoya Proton Therapy Center, 1-1-1 Hirate-cho, Kita-ku, Nagoya 462-8508, Japan.

Toshiyuki Toshito (T)

Department of Proton Therapy Physics, Nagoya Proton Therapy Center, 1-1-1 Hirate-cho, Kita-ku, Nagoya 462-8508, Japan.

Shingo Hashimoto (S)

Department of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.

Koichiro Nakajima (K)

Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City West Medical Center, 1-1-1 Hirate-cho, Kita-ku, Nagoya 462-8508, Japan.
Department of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.

Chikao Sugie (C)

Department of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.

Hiroyuki Ogino (H)

Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City West Medical Center, 1-1-1 Hirate-cho, Kita-ku, Nagoya 462-8508, Japan.
Department of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.

Hirofumi Kai (H)

Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto, 862-0973, Japan.

Yuta Shibamoto (Y)

Department of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH